VBI Vaccines (NASDAQ:VBIV) Share Price Crosses Below Two Hundred Day Moving Average of $0.62

VBI Vaccines Inc. (NASDAQ:VBIV) shares passed below its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $0.62 and traded as low as $0.60. VBI Vaccines shares last traded at $0.60, with a volume of 189,719 shares.

Analyst Upgrades and Downgrades

Separately, StockNews.com started coverage on VBI Vaccines in a research note on Thursday. They issued a “sell” rating on the stock.

VBI Vaccines Stock Performance

The company has a 50 day simple moving average of $0.62 and a two-hundred day simple moving average of $0.62.

VBI Vaccines (NASDAQ:VBIV) last released its earnings results on Wednesday, May 15th. The biopharmaceutical company reported ($0.55) earnings per share for the quarter, missing the consensus estimate of ($0.53) by ($0.02). VBI Vaccines had a negative net margin of 881.79% and a negative return on equity of 525.42%. The business had revenue of $1.21 million for the quarter, compared to analysts’ expectations of $2.85 million. As a group, equities research analysts forecast that VBI Vaccines Inc. will post -1.23 earnings per share for the current year.

VBI Vaccines Company Profile

VBI Vaccines Inc, a commercial-stage biopharmaceutical company, develops and sells vaccines to treat immuno-oncology and infectious disease. It offers Sci-B-Vac, a prophylactic hepatitis B (HBV) vaccine. The company also develops VBI-2601, a protein based immunotherapeutic candidate for the treatment of chronic HBV infection; VBI-1901, a glioblastoma vaccine immunotherapeutic candidate, which is in Phase I/IIa clinical study to treat solid tumors; VBI-1501, a prophylactic cytomegalovirus vaccine candidate that has completed Phase I clinical trial; and VBI-2501 that is in preclinical trial to treat Zika virus.